AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20423835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone, 100 mg daily (n = 33)
Number of subjects: 65
Study 18657667 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 65
Study 18657667 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone, 100 mg daily
Number of subjects: 65
Study 18657667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 15113461 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 171
Study 15113461 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 171
Study 12516488 — intervention group
Group type: EXPERIMENTAL
Intervention: 27G Sprotte needle
Number of subjects: 389
Study 12516488 — intervention group
Group type: EXPERIMENTAL
Intervention: 29G Sprotte needle
Number of subjects: 389
Study 12516488 — intervention group
Group type: COMPARATOR
Intervention: Technical difficulty with 29G needle
Number of subjects: 389
Study 9666777 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral alprostadil therapy
Number of subjects: 249
Study 9666777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 8576819 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase-digested (AMD) corn porridge
Number of subjects: 75
Study 8576819 — intervention group
Group type: COMPARATOR
Intervention: Conventional corn porridge
Number of subjects: 75
Study 8576819 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented and amylase-digested (FAD) corn porridge
Number of subjects: 75
Study 2663800 — intervention group
Group type: EXPERIMENTAL
Intervention: Testolactone (2 g/day)
Number of subjects: 25
Study 2663800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 208439 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25(OH)2D3 (0.5 to 1.5 microgram/day)
Number of subjects: 31
Study 208439 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 (400 to 1200 IU/day)
Number of subjects: 31
Study 31187344 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 614
Study 31187344 — intervention group
Group type: EXPERIMENTAL
Intervention: Emailed feedback (EF)
Number of subjects: 614
Study 31187344 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 614
Study 28716314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen 400 mg
Number of subjects: 83
Study 28716314 — intervention group
Group type: COMPARATOR
Intervention: Ebselen 200 mg
Number of subjects: 83
Study 28716314 — intervention group
Group type: COMPARATOR
Intervention: Ebselen 600 mg
Number of subjects: 83
Study 28716314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 26568588 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 50 mg/week
Number of subjects: 90
Study 26568588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23223314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (4-10 ng/mL) and prednisolone 5 mg/day
Number of subjects: 32
Study 20926750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (1 mg/h continuous intravenous infusion for 6 hours)
Number of subjects: 17
Study 19348851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy bone removal CTA
Number of subjects: 52
Study 19348851 — intervention group
Group type: COMPARATOR
Intervention: Conventional bone-subtraction CTA
Number of subjects: 52
Study 16753335 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 12
Study 16753335 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 12
Study 16753335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15300265 — intervention group
Group type: EXPERIMENTAL
Intervention: Open haemorrhoidectomy (group A)
Number of subjects: 79
Study 15300265 — intervention group
Group type: COMPARATOR
Intervention: Closed haemorrhoidectomy (group B)
Number of subjects: 79
Study 15300265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of management
Number of subjects: 79
Study 11687611 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI)
Number of subjects: 12
Study 11687611 — intervention group
Group type: COMPARATOR
Intervention: Continuous highly active antiretroviral therapy (HAART)
Number of subjects: 12
Study 10423615 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg corn-oil suspension
Number of subjects: 16
Study 10423615 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg corn-oil suspension
Number of subjects: 16
Study 10423615 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg corn-oil suspension
Number of subjects: 16
Study 10423615 — intervention group
Group type: COMPARATOR
Intervention: Osteofix tablet
Number of subjects: 16
Study 8175218 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment (6.25 mg orally about 15 min before thrombolysis) in Group A
Number of subjects: 259
Study 8175218 — intervention group
Group type: COMPARATOR
Intervention: Captopril late-treatment (administered about 3 days after thrombolysis) in Group B
Number of subjects: 259
Study 8175218 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril pretreatment in Group A
Number of subjects: 259
Study 8175218 — intervention group
Group type: COMPARATOR
Intervention: Captopril late-treatment in Group B
Number of subjects: 259
Study 3431098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quik Test Drug Screen for detection of benzoylecgonine
Number of subjects: 100
Study 3431098 — intervention group
Group type: COMPARATOR
Intervention: TDx assay for cocaine metabolite
Number of subjects: 100
Study 3431098 — intervention group
Group type: EXPERIMENTAL
Intervention: Quik Test Drug Screen for benzoylecgonine
Number of subjects: 100
Study 30172948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30172948 — intervention group
Group type: COMPARATOR
Intervention: β1-preferential antagonist (10 mg bisoprolol)
Number of subjects: 14
Study 30172948 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-preferential β1 + β2-antagonist (80 mg nadolol)
Number of subjects: 14
Study 30172948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 14
Study 29894607 — intervention group
Group type: COMPARATOR
Intervention: Anesthetic cardioprotection
Number of subjects: 92
Study 29894607 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 92
Study 29894607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study 29894607 — intervention group
Group type: COMPARATOR
Intervention: VIMA group
Number of subjects: 92
Study 24193868 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (ES) combined with radiotherapy
Number of subjects: 80
Study 24193868 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 80
Study 23879079 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate daily)
Number of subjects: 60
Study 23879079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20337616 — intervention group
Group type: EXPERIMENTAL
Intervention: New anaesthetic drug administration system
Number of subjects: 74478
Study 20337616 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 74478
Study 18065810 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 35
Study 18065810 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX)
Number of subjects: 35
Study 16427266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily via HFA-MDI without a spacer
Number of subjects: 359
Study 16427266 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 320 microg once daily
Number of subjects: 359
Study 14688490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drug therapy
Number of subjects: 0
Study 14688490 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-drug therapy
Number of subjects: 0
Study 10823524 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 2 microg/kg subcutaneously once a day for 5 days
Number of subjects: 30
Study 10823524 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 30
Study 8789682 — intervention group
Group type: EXPERIMENTAL
Intervention: One change per week
Number of subjects: 447
Study 8789682 — intervention group
Group type: COMPARATOR
Intervention: Three changes per week
Number of subjects: 447
Study 1730830 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine diphosphate (0.01 mg/ml)
Number of subjects: 24
Study 1730830 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine diphosphate (0.05 mg/ml)
Number of subjects: 24
Study 1730830 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine diphosphate (dose-response curve)
Number of subjects: 24
Study 1730830 — intervention group
Group type: COMPARATOR
Intervention: Diluent (control)
Number of subjects: 24
Study 3707675 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal alcohol (5.0%, v/v) beer
Number of subjects: 48
Study 3707675 — intervention group
Group type: COMPARATOR
Intervention: Low alcohol (0.9%, v/v) beer
Number of subjects: 48
Study 31505244 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptome sequencing from seeds, leaves, and flowers
Number of subjects: 14
Study 31505244 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation of 120 randomly selected primers
Number of subjects: 14
Study 29266564 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial
Number of subjects: 7011
Study 27233139 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness descriptors selected by patients
Number of subjects: 132
Study 27233139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of breathlessness descriptors
Number of subjects: 132
Study 24339234 — intervention group
Group type: EXPERIMENTAL
Intervention: XP21279-carbidopa (3 times daily)
Number of subjects: 35
Study 24339234 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa (4 or 5 times daily)
Number of subjects: 35
Study 24339234 — intervention group
Group type: EXPERIMENTAL
Intervention: XP21279-carbidopa
Number of subjects: 35
Study 24339234 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa
Number of subjects: 35
Study 22858926 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted allergen avoidance (breastfeeding with low allergen diet or extensively hydrolysed formula, reduced exposure to house dust mite allergen)
Number of subjects: 120
Study 22858926 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard advice)
Number of subjects: 120
Study 22858926 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted allergen avoidance
Number of subjects: 120
Study 22858926 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 20060973 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 889
Study 20060973 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 889
Study 18668391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic RBCs
Number of subjects: 0
Study 18668391 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NPBI, esterified F(2)-IsoPs, and AOPP in diabetic patients
Number of subjects: 0
Study 18668391 — intervention group
Group type: COMPARATOR
Intervention: Control RBCs
Number of subjects: 0
Study 18279468 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Failure Patients (HF)
Number of subjects: 169
Study 15017179 — intervention group
Group type: EXPERIMENTAL
Intervention: omafilcon A
Number of subjects: 20
Study 15017179 — intervention group
Group type: EXPERIMENTAL
Intervention: polymacon
Number of subjects: 20
Study 15017179 — intervention group
Group type: EXPERIMENTAL
Intervention: phemfilcon A
Number of subjects: 20
Study 15017179 — intervention group
Group type: EXPERIMENTAL
Intervention: balafilcon A
Number of subjects: 20
Study 15017179 — intervention group
Group type: EXPERIMENTAL
Intervention: etafilcon A
Number of subjects: 20
Study 15017179 — intervention group
Group type: EXPERIMENTAL
Intervention: All contact lenses
Number of subjects: 20
Study 11372005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (0.3 mmol/kg/h)
Number of subjects: 30
Study 11372005 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 30
Study 11372005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 30
Study 9416716 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 microg/kg oral clonidine
Number of subjects: 72
Study 9416716 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 microg/kg oral clonidine
Number of subjects: 72
Study 9416716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 72
Study 9416716 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide (60%) with control
Number of subjects: 72
Study 9416716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (60%) with 2 microg/kg clonidine
Number of subjects: 72
Study 9416716 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (60%) with 4 microg/kg clonidine
Number of subjects: 72
Study 8480273 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg, orally, four times a day)
Number of subjects: 180
Study 8480273 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSO (500 mg, orally, four times a day)
Number of subjects: 180
Study 8480273 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 180
Study 3687360 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 100
Study 3687360 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 100
Study 3687360 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA + GA
Number of subjects: 100
Study 28802292 — intervention group
Group type: EXPERIMENTAL
Intervention: White Rice (WR)
Number of subjects: 25
Study 28802292 — intervention group
Group type: EXPERIMENTAL
Intervention: Under Milled Rice (UMR)
Number of subjects: 25
Study 28802292 — intervention group
Group type: COMPARATOR
Intervention: Brown Rice (BR)
Number of subjects: 25
Study 25321394 — intervention group
Group type: EXPERIMENTAL
Intervention: danoprevir 100 mg twice daily
Number of subjects: 40
Study 25321394 — intervention group
Group type: EXPERIMENTAL
Intervention: danoprevir 200 mg three times daily
Number of subjects: 40
Study 25321394 — intervention group
Group type: EXPERIMENTAL
Intervention: danoprevir 300 mg twice daily
Number of subjects: 40
Study 25321394 — intervention group
Group type: EXPERIMENTAL
Intervention: danoprevir (various doses)
Number of subjects: 40
Study 23988799 — intervention group
Group type: EXPERIMENTAL
Intervention: Parker Flex‐It intubation stylet
Number of subjects: 20
Study 23988799 — intervention group
Group type: COMPARATOR
Intervention: 90-degree curved stylet
Number of subjects: 20
Study 21097793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification to improve weight
Number of subjects: 216
Study 19922626 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 or 40 mg once daily
Number of subjects: 149
Study 16752526 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal cardioversion (8 +/- 3.13 joules)
Number of subjects: 31
Study 16752526 — intervention group
Group type: COMPARATOR
Intervention: External cardioversion (200-360 joules)
Number of subjects: 31
Study 15521346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% Nitroglycerin ointment (0.75 mg)
Number of subjects: 48
Study 15521346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% Nitroglycerin ointment (1.5 mg)
Number of subjects: 48
Study 15521346 — intervention group
Group type: COMPARATOR
Intervention: 0% Nitroglycerin ointment (placebo)
Number of subjects: 48
Study 11744583 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal ketoprofen
Number of subjects: 63
Study 11744583 — intervention group
Group type: COMPARATOR
Intervention: Placebo tape treatment (control group)
Number of subjects: 63
Study 9250445 — intervention group
Group type: COMPARATOR
Intervention: Snack (240 ml of 2% milk plus one slice of toast, approximately 200 kcal)
Number of subjects: 15
Study 9250445 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine (40 g, plus 10 g of glucose, approximately 200 kcal)
Number of subjects: 15
Study 9250445 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5.0 mg)
Number of subjects: 15
Study 9250445 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 15
Study 8389103 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,219 (400 micrograms)
Number of subjects: 9
Study 8389103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3436157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (600 mg/day) with glibenclamide (5 to 15 mg/day)
Number of subjects: 64
Study 3436157 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg/day) with glibenclamide (5 to 15 mg/day)
Number of subjects: 64
Study 3436157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (600 mg/day) with chlorpropamide (250 to 500 mg/day)
Number of subjects: 64
Study 3436157 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg/day) with chlorpropamide (250 to 500 mg/day)
Number of subjects: 64
Study 30549487 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 450
Study 27317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid 300 mg once daily
Number of subjects: 40
Study 27317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid 400 mg once daily
Number of subjects: 40
Study 27317442 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily
Number of subjects: 40
Study 27317442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 27317442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily
Number of subjects: 40
Study 25256183 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (7 days treatment)
Number of subjects: 274
Study 22703742 — intervention group
Group type: EXPERIMENTAL
Intervention: Brunnstrom hand manipulation (BHM)
Number of subjects: 30
Study 22703742 — intervention group
Group type: COMPARATOR
Intervention: Motor Relearning Program (MRP)
Number of subjects: 30
Study 20831450 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 195
Study 20831450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 18976976 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh (woven polyester or polypropylene)
Number of subjects: 322
Study 18976976 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded polytrafluroethylene (ePTFE) mesh
Number of subjects: 322
Study 18976976 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent hysterectomy
Number of subjects: 322
Study 18976976 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 322
Study 18976976 — intervention group
Group type: COMPARATOR
Intervention: Observation (no intervention)
Number of subjects: 322
Study 16093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 33
Study 16093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 33
Study 16093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg)
Number of subjects: 33
Study 16093747 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 33
Study 16093747 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental pain assessment
Number of subjects: 33
Study 11521797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for five days during weeks one and four of radiotherapy
Number of subjects: 31
Study 11521797 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day chemotherapy regimen with Mitomycin C 12 mg/m2 day 1 and 5‐fluorouracil 500 mg/m2/24 hours for seven days during weeks one and four of radiotherapy
Number of subjects: 31
Study 11521797 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (chemoradiotherapy)
Number of subjects: 31
Study 9846284 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 13
Study 9846284 — intervention group
Group type: COMPARATOR
Intervention: Flomoxef
Number of subjects: 13
Study 8279372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 17
Study 8279372 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 17
Study 2662291 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (0.1 mg/puff, 2 puffs t.d.s. for 4 weeks)
Number of subjects: 20
Study 2662291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2662291 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20
Study 30730774 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 134
Study 30730774 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative and Proactive Solutions (CPS)
Number of subjects: 134
Study 30730774 — intervention group
Group type: EXPERIMENTAL
Intervention: Family permissiveness
Number of subjects: 134
Study 29790780 — intervention group
Group type: EXPERIMENTAL
Intervention: One-quarter per day activation protocol
Number of subjects: 101
Study 29790780 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-quarters per day activation protocol
Number of subjects: 101
Study 29790780 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects, 11 females and 9 males, mean age 10.27 ± 1.24 years)
Number of subjects: 101
Study 27681767 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum dose of radiation therapy (RT)
Number of subjects: 33
Study 24520780 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) intervention (Jianpi Shugan Recipe)
Number of subjects: 204